Corbus Pharmaceuticals Holdings (CRBP) Cash & Current Investments (2013 - 2025)

Corbus Pharmaceuticals Holdings' Cash & Current Investments history runs 13 years deep, the most recent figure standing at $163.3 million for Q4 2025.

• In Q4 2025, Cash & Current Investments rose 9.53% year-over-year to $163.3 million; the TTM figure through Dec 2025 stood at $163.3 million (up 9.53% YoY), while the FY2025 annual figure was $163.3 million, up 9.53% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $163.3 million, up from $104.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $163.3 million in Q4 2025, with the low at $20.9 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $105.2 million (2021), against an average of $97.1 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments slumped 64.68% in 2023, then jumped 613.01% in 2024.
• Corbus Pharmaceuticals Holdings' Cash & Current Investments stood at $97.6 million in 2021, then slumped by 39.38% to $59.2 million in 2022, then plunged by 64.68% to $20.9 million in 2023, then surged by 613.01% to $149.1 million in 2024, then climbed by 9.53% to $163.3 million in 2025.
• Business Quant data shows CRBP's Cash & Current Investments at $163.3 million in Q4 2025, $104.0 million in Q3 2025, and $116.6 million in Q2 2025.